COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
iFabric Corp. Receives FDA Medical Device Registration for Apparel Products Utilizing Multiple Textile Technologies
iFabric Corp.'s subsidiary IFTNA obtains FDA registration for medical device, showcasing commitment to textile innovation in healthcare. CEO Beevis highlights benefits and growth opportunities -
COMMUNIQUÉ DE PRESSE
Planet 13 Launches New MEDIZIN Branded Topicals - Introducing MEDIZIN Rest, Recovery and Relief
Planet 13 Holdings Inc. introduces new CBD hemp and cannabis derived topical line under the MEDIZIN brand, expanding product offerings and revenue streams. The topicals incorporate Ovation Science's Invisicare® technology for enhanced delivery of cannabinoids -
COMMUNIQUÉ DE PRESSE
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
NanoViricides reports successful completion of Phase I Clinical Trial of NV-387, progresses towards Phase II discussion with physicians and experts for dosing protocol determination -
-
COMMUNIQUÉ RÉGLEMENTÉ
Annual Ordinary Shareholders’ Meeting of May 23, 2024, availability of preliminary documents for the Annual General Meeting
Safran announces availability of preliminary documents for the Annual Ordinary Shareholders' Meeting to be held on May 23, 2024 at Safran Campus, Massy, France -
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
MindBio Therapeutics Corp. has received regulatory approval for clinical trials using MB22001 to address PMS and PMDD in menstruating individuals. The trials aim to assess the drug's mood-related effects during different menstrual phases
